CoChat

Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial

Martinotti, Giovanni, Di Nicola, Marco, Frustaci, Alessandra, Romanelli, Roberto, Tedeschi, Daniela, Guglielmo, Riccardo, Guerriero, Luigi, Bruschi, Angelo, De Filippis, Rocco, Pozzi, Gino, Di Giannantonio, Massimo, Bria, Pietro, Janiri, Luigi · 2010 · Addiction
Cited by 83

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Introduction The aim of this trial was to compare lorazepam with non‐benzodiazepine medications such as pregabalin and tiapride in the treatment of alcohol withdrawal syndrome (AWS). These drugs were chosen for their inhibitorial effects on the hypersecretion of neurotransmitters usually observed in AWS. Craving reduction and improvement of psychiatric symptoms were the secondary end‐points. Methods One hundred and ninety subjects affected by current alcohol dependence were considered consecutively: 111 were enrolled and divided into three groups of 37 subjects each. Within a treatment duration of 14 days, medication was given up to the following maximum doses (pregabalin 450 mg/day; tiapride 800 mg/day; lorazepam 10 mg/day). Withdrawal (CIWA‐Ar), craving [visual analogue scale (VAS); Obsessive and Compulsive Drinking Scale (OCDS)], psychiatric symptoms [Symptom Check List 90 Revised (SCL‐90‐R)] and quality of life (QL‐index) rating scales were applied. Results On the CIWA‐Ar score, all the groups showed a significant reduction between times (P < 0.001) with a higher reduction for the pregabalin group (P < 0.01) on items regarding headache and orientation. Retention in treatment was lower in the tiapride group (P < 0.05), while the number of subjects remaining alcohol free was higher in the pregabalin group (P < 0.05). Significant reduction between baseline and the end of the treatment was found in all the groups at the OCDS and the VAS for craving, at the SCL‐90‐R and QL‐index (P < 0.001). Discussion All the medications in the trial showed evidence of safety and efficacy in the treatment of uncomplicated forms of AWS, with some particular differences. The efficacy of pregabalin was superior to that of tiapride, used largely in research trials and, for some measures, to that of the ‘gold standard’, lorazepam. Accordingly, pregabalin may be considered as a potentially useful new drug for treatment of AWS, deserving further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2009.02792.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 83

Metadata

Authors
Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., Di Giannantonio, M., Bria, P., & Janiri, L.
Venue
Addiction
Publisher
Wiley
Published
2010-01-11
Volume
105
Issue
2
Pages
288-299
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W1978434699
Cited by
83
References
8
FWCI
5.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial. https://app.cochat.ai/papers/10.1111/j.1360-0443.2009.02792.x
The paper
Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., Di Giannantonio, M., Bria, P., & Janiri, L. (2010). Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02792.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.